Trial · NCT00075608
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
NCT00075608, Phase 2, Terminated, Boston Medical Center; results first posted 2017-01-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis. Trials, record NCT00075608. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00075608
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
- NCT number
- NCT00075608
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Boston Medical Center
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- filgrastim, melphalan, autologous stem cell transplantation, stem cell infusion
- First posted
- 2004-01-12
- Last updated
- 2017-01-27
- Results first posted
- 2017-01-27
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility and Tolerability | 3 months after treatment and annually | Feasibility and tolerability will be evaluated based on participants completing second transplant with tolerable adverse events |
| Primary | Response and Durability of Response | 3 months after treatment and annually | Response and durability of response will be based on hematologic Complete Response or Partial Response and date of relapse or death |
| Primary | Evaluate Immune Reconstitution | 3 months after treatment and annually | Evaluate immune reconstitution based on time to engraftment |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Feasibility and Tolerability | 3 months after treatment and annually | No data were collected or analyzed due to study termination | ||
| PRIMARY | Response and Durability of Response | 3 months after treatment and annually | No data were collected or analyzed due to study termination | ||
| PRIMARY | Evaluate Immune Reconstitution | 3 months after treatment and annually | No data were collected or analyzed due to study termination |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Second Transplant | 12 | |
| Overall Study | COMPLETED | Second Transplant | 12 | |
| Overall Study | NOT COMPLETED | Second Transplant | 0 |
Source ClinicalTrials.gov
Adverse events14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | nausea | Gastrointestinal disorders | Second Transplant | 9 | 12 | 13 |
| other | diarrhea | Gastrointestinal disorders | Second Transplant | 5 | 12 | 6 |
| other | peripheral edema | Blood and lymphatic system disorders | Second Transplant | 2 | 12 | 2 |
| other | dyspnea | Respiratory, thoracic and mediastinal disorders | Second Transplant | 3 | 12 | 3 |
| other | hypocalcemia | Investigations | Second Transplant | 2 | 12 | 2 |
| other | hypoalbuminemia | Investigations | Second Transplant | 3 | 12 | 3 |
| serious | Sepsis | Blood and lymphatic system disorders | Second Transplant | 2 | 12 | 3 |
| serious | febrile neutropenia | Infections and infestations | Second Transplant | 8 | 12 | 8 |
| serious | Acute renal failure | Renal and urinary disorders | Second Transplant | 2 | 12 | 2 |
| serious | fatigue | General disorders | Second Transplant | 8 | 12 | 8 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Second Transplant | ||
| Total, other adverse events | Second Transplant | 12 | 12 |
| Total, serious adverse events | Second Transplant | 12 | 12 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00075608
GET https://conductscience.org/api/trials/v1/NCT00075608/registered